Novel therapies in axial spondyloarthritis

Elsevier

Available online 22 December 2022, 101811

Best Practice & Research Clinical RheumatologyAuthor links open overlay panelAbstract

Over the past two decades, advancements in understanding the pathogenesis of axial spondyloarthritis have led to discoveries of new therapeutic targets, particularly the interleukin-17, tumor necrosis factor axis, and Janus kinase-signal transducer and activator of transcription pathway. While many of the available agents have proven to be efficacious and safe for the treatment of axial spondyloarthritis, a remarkable percentage of patients either fail or cannot tolerate these medications. This has prompted researchers to look for new targets that would maximize efficacy and minimize toxicity. In this article, we review novel agents that were recently approved, in trials, and possible future targets or mechanisms. We also discuss their role as it pertains to the prevention of radiographic progression and the management of extra-musculoskeletal manifestations.

Keywords

Axial spondyloarthritis

Ankylosing spondylitis

Novel therapies

Treatment

Biologics

Small molecules

View full text

© 2022 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif